FY24 consensus $10.01. Raises FY24 operational revenue view to $89.2B-$89.6B from $88.7B-$89.1B, consensus $88.74B. Johnson & Johnson is updating its 2024 guidance, including adjusted operational EPS guidance, to reflect improved performance and the impact for the recent acquisitions of Shockwave Medical, Proteologix, and NM26 Bispecific Antibody.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Stock Market News Today, 7/17/24 – Futures Down After a Strong Session
- 3 Reasons Johnson & Johnson (NYSE:JNJ) Is an Attractive Dividend Growth Stock
- Johnson & Johnson (JNJ) Q2 Earnings Preview: Here’s What to Expect
- Johnson & Johnson Stock (NYSE:JNJ): The Best Buying Opportunity in Over a Decade?
- Stock Market News Today, 7/15/24 – Indices Close Higher amid Powell’s Praise